Tag: TME
TME Pharma: Further improvement in median overall survival at 19 months in the GLORIA trial on brain cancer
By Claude Leguilloux Published on 12/20/2023 at 8:01 a.m. Photo credit © ChaunuPictures (Boursier.com) — TME Pharma NV,…
TME Pharma announces a capital increase of 2.7 million euros
(AOF) – TME Pharma announced the launch of a 100% guaranteed capital increase of 2.7 million euros through the issue of new shares associated with subscription warrants making it possible…
TME PHARMA LAUNCHES A FULLY GUARANTEED CAPITAL INCREASE OF €2.7 M WITH PREFERENTIAL SUBSCRIPTION RIGHTS (DPS) FOR SHARES ASSOCIATED WITH SUBSCRIPTION VOUCHERS (ABSA) AND ANNOUNCES THE PURCHASE OF PART OF ITS CONVERTIBLE DEBT – 24/11 /2023 at 6:15 p.m.
Attention ! This investment does not fall within the scope of AMF control. No license and no prospectus is required for this activityThis information is not intended for residents of…
TME Pharma announces a capital increase of 2.7 million euros – 11/24/2023 at 6:16 p.m.
(AOF) – TME Pharma announced the launch of a 100% guaranteed capital increase of 2.7 million euros through the issue of new shares associated with subscription warrants making it possible…
TME PHARMA ANNOUNCES THE PRESENTATION OF ADDITIONAL DATA ON COMBINATION TREATMENT OF NOX-A12 IN BRAIN CANCER AT THE SNO 2023 ANNUAL MEETING – 11/18/2023 at 08:00
TME PHARMA ANNOUNCES PRESENTATION OF ADDITIONAL DATA ON COMBINATION TREATMENT OF NOX-A12 IN BRAIN CANCER AT SNO 2023 ANNUAL MEETING • Substantial improvement in survival and progression-free survival in NOX-A12…
TME PHARMA PUBLISHES ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2023 AND PROVIDES AN UPDATE ON ITS ACTIVITY – 10/27/2023 at 6:00 p.m.
• Survival data from the phase 1/2 NOX-A12 GLORIA trial in brain cancer continues to improve and has already exceeded that of all competing treatments. • 67% overall survival at…
TME Pharma: 3 million euros in cash as of June 30, visibility until February 2024 – 10/27/2023 at 6:17 p.m.
(AOF) – “Given cash and cash equivalents of 3 million euros as of June 30, 2023”, TME Pharma “has financial visibility until February 2024”. This is what the biotech specialist…
TME Pharma: 3 million euros in cash as of June 30, visibility until February 2024
(AOF) – “Given cash and cash equivalents of 3 million euros as of June 30, 2023”, TME Pharma “has financial visibility until February 2024”. This is what the biotech specialist…
TME Pharma: new data in brain cancer – 10/20/2023 at 11:45
(CercleFinance.com) – TME Pharma reported new positive data on Friday in aggressive brain cancer in adults, which allowed its stock to rebound on Friday on the Paris Stock Exchange. The…
TME PHARMA ANNOUNCES THE END OF THE SIX-MONTH LOCK-UP PERIOD OF SHARES AND CONVERTIBLE BONDS FOLLOWING THE APRIL 2023 FINANCIAL TRANSACTION – 10/17/2023 at 7:00 p.m.
Berlin, Germany, October 17, 2023, 7:00 p.m. CEST – TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of novel therapies for the treatment of…
TME Pharma: a tumor has completely disappeared in a patient
AB Published on 07/13/2023 at 08:37 (Boursier.com) — TME Pharma Announces Positive Best Response Clinical Update, Reporting Patient Complete Response…
TME Pharma: positive results in brain tumors – 06/30/2023 at 18:02
(CercleFinance.com) – TME Pharma announced on Wednesday that a study had shown that 83% of patients with glioblastoma, a brain cancer, were still alive after 15 months of treatment, “unheard…